Wall Street analysts expect Audentes Therapeutics (NASDAQ:BOLD) to announce earnings of ($0.77) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Audentes Therapeutics’ earnings, with estimates ranging from ($0.79) to ($0.73). Audentes Therapeutics posted earnings per share of ($0.87) during the same quarter last year, which would indicate a positive year-over-year growth rate of 11.5%. The business is expected to report its next earnings results on Thursday, August 9th.
On average, analysts expect that Audentes Therapeutics will report full year earnings of ($3.31) per share for the current fiscal year, with EPS estimates ranging from ($4.22) to ($2.98). For the next financial year, analysts forecast that the firm will report earnings of ($3.63) per share, with EPS estimates ranging from ($4.32) to ($3.14). Zacks’ EPS averages are an average based on a survey of research analysts that follow Audentes Therapeutics.
Audentes Therapeutics (NASDAQ:BOLD) last issued its quarterly earnings results on Wednesday, May 9th. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.07.
BOLD has been the subject of a number of analyst reports. Zacks Investment Research upgraded Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price target for the company in a research report on Thursday, March 8th. HC Wainwright set a $37.00 price target on Audentes Therapeutics and gave the stock a “buy” rating in a research report on Friday, March 9th. Wedbush restated an “outperform” rating and issued a $56.00 price target on shares of Audentes Therapeutics in a research report on Friday, March 9th. Cowen reiterated a “buy” rating on shares of Audentes Therapeutics in a research report on Friday, March 9th. Finally, Raymond James reiterated a “hold” rating on shares of Audentes Therapeutics in a research report on Thursday, May 17th. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $37.22.
BOLD traded up $0.47 during trading on Friday, reaching $41.59. The company had a trading volume of 1,702,775 shares, compared to its average volume of 448,691. The company has a market cap of $1.57 billion, a PE ratio of -12.23 and a beta of 1.15. Audentes Therapeutics has a 52 week low of $15.74 and a 52 week high of $46.18.
In other news, VP Suyash Prasad sold 1,900 shares of the firm’s stock in a transaction on Monday, March 26th. The stock was sold at an average price of $30.00, for a total transaction of $57,000.00. Following the transaction, the vice president now owns 1,900 shares in the company, valued at $57,000. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP David Nagler sold 5,000 shares of the firm’s stock in a transaction on Wednesday, June 20th. The shares were sold at an average price of $45.29, for a total value of $226,450.00. Following the transaction, the senior vice president now owns 4,700 shares in the company, valued at approximately $212,863. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 83,700 shares of company stock valued at $2,699,856. Corporate insiders own 6.60% of the company’s stock.
Several institutional investors have recently made changes to their positions in BOLD. Tortoise Investment Management LLC purchased a new position in shares of Audentes Therapeutics during the first quarter valued at $112,000. Cubist Systematic Strategies LLC purchased a new position in shares of Audentes Therapeutics during the first quarter valued at $204,000. Teacher Retirement System of Texas purchased a new position in shares of Audentes Therapeutics during the fourth quarter valued at $208,000. MetLife Investment Advisors LLC purchased a new position in shares of Audentes Therapeutics during the fourth quarter valued at $248,000. Finally, California Public Employees Retirement System purchased a new position in shares of Audentes Therapeutics during the first quarter valued at $322,000. Hedge funds and other institutional investors own 94.23% of the company’s stock.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT982, which is in preclinical studies for the treatment of pompe disease; and AT307 that is in preclinical studies to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.